A Randomized, Controlled, Multi-center Collaborative Phase IV Study to Evaluate the Safety and Efficacy of Decitabine in Myelodysplastic Syndrome
Latest Information Update: 15 Jan 2019
At a glance
- Drugs Decitabine (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Acronyms DREAM
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 04 Dec 2018 Status changed from recruiting to completed, according to the results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 04 Dec 2018 Final results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 06 Jan 2014 New trial record